Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that the Company’s CEO, James McIlroy, was awarded the title of ‘Young Pioneer of the Year’ at the inaugural Herald Scotland business awards.
The event, held at Glasgow Science Centre, recognised and rewarded innovation and sustainability at an international level, across all business sectors. The awards attracted entries from across the UK, from Aberdeen to London, as well as from the European mainland. It celebrated cross-sectoral innovators pioneering new ideas and products, particularly those helping to deliver a sustainable future and advance the United Nations Sustainable Development Goals.
Roy Gardner, executive director at City of Glasgow College, said: “Our congratulations go to a well-deserved winner whose ground-breaking project is helping to address and bridge the gender gap in STEM.”
For further information, please see the official article on the Herald website.
EnteroBiotix is harnessing the human microbiome to develop novel medicinal products that restore health and prevent disease. The company’s first focus is to unlock the full therapeutic potential intestinal microbiome transfer through two core product portfolios targeting gastrointestinal diseases and infections caused by bacteria such as C.difficile. EnteroBiotix has established deep operational experience and capabilities, including fully integrated ISO-accredited microbial collection and GMP-compliant clean room manufacturing facilities under a manufacturer’s specials license (License Number: MS 49464) and an MIA (IMP) license (License Number: MIA(IMP) 49464) from the Medicines and Healthcare Products Regulatory Agency (MHRA). Since its formation in March 2017, EnteroBiotix has raised over £2.5m in seed investment and has distributed its market entry, minimally manipulated medicinal products on a named patient basis around Europe. EnteroBiotix has offices in Aberdeen, Scotland, and Boston, USA.
For further information, please contact:
James McIlroy, CEO